TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female Japanese subjects, age at least 20 years at the time of signing informed consent~* Type 2 diabetes subjects (diagnosed clinically) at least 6 months prior to screening~* HbA1c (glycosylated haemoglobin) 7.0-11.0 % (both inclusive) by central laboratory analysis, with the aim of a median of 8.3%. When approximately 50% of the randomised subjects have a HbA1c above 8.3%, the remaining subjects randomised must have a HbA1c below or equal to 8.3%; or when approximately 50% of the randomised subjects have a HbA1c below or equal to 8.3%, the remaining subjects randomised must have a HbA1c above 8.3%~* Body-mass index (BMI) above or equal to 20 kg/m\^2~* Subjects on stable therapy with one OAD (defined as unchanged medication and unchanged dose) for at least 60 days (metformin, a-GI, TZD, SU, SGLT2i or glinide) prior to screening according to approved Japanese labelling~Exclusion Criteria:~* Previous treatment with insulin (except for short-term treatment in connection with intercurrent illness including gestational diabetes)~* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 60 days before screening~* Anticipated initiation or change in concomitant medications in excess of 14 days known to affect weight or glucose metabolism~* Impaired liver function, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) equal to or above 2.5 times upper limit of normal~* Renal impairment estimated Glomerular Filtration Rate (eGFR) below 60mL/min/1.73m\^2 as per Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)~* Screening calcitonin equal to or above 50 ng/L~* History of pancreatitis (acute or chronic)~* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)~* Subjects presently classified as being in New York Heart Association (NYHA) Class IV

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin degludec/liraglutide OD (Type: EXPERIMENTAL): None
- Insulin degludec OD (Type: ACTIVE_COMPARATOR): None
- Liraglutide OD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Screening Visit~  * Age: 19-80~ * High risk for cardiovascular disease according to NCEP APT III~ * TG≥130mg/dL and 160mg/dL\>LDL-C≥100mg/dL for subjects who were not taking statins for 4 weeks~ * 500mg/dL\>TG≥200mg/dL and LDL-C\<110mg/dL for subjects who were taking statins for 4 weeks~* Baseline Visit~  * 500mg/dL\>TG≥200mg/dL~ * LDL-C\<110mg/dL~ * Reduction of LDL-C dompairng screening visit~Exclusion criteria:~* The patient has histories of acute artery disease within 3 months~* The patient has histories of operation revasculatiation or aneurysm within 6 months~* The patient has histories of Unexplained myaliga or diagnosed myalgia or rhabdomyolysis~* The patient has histories of Effectable disease to the procedrue and clinical trial result

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): KI1107
- Control (Type: ACTIVE_COMPARATOR): Rosuvastatin calcium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure (DBP) must be \>=90 and \<=114 mmHg and mean seated systolic blood pressure (SBP) must be =\<200 mmHg~2. Able to stop all current antihypertensive drugs (other than study medication) from Visit 1b through the end of the trial without risk to the patient based on the investigator's opinion~3. Age 20 years or older~Exclusion criteria:~1. Patients with known or suspected secondary hypertension~2. Patients with clinically relevant cardiac arrhythmia~3. Congestive heart failure with New York Heart Association (NYHA) functional class III-IV~4. Patients with recent cardiovascular events~5. Patients with recent stroke events~6. Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers or angiotensin converting enzyme inhibitors; or patients with post-renal transplant or post-nephrectomy~7. Patients with hepatic and/or renal dysfunction~8. Pre-menopausal women who are nursing or pregnant

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- telmisartan + HCTZ + amlodipine (Type: EXPERIMENTAL): telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
- telmisartan + HCTZ + placebo (Type: ACTIVE_COMPARATOR): telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Medications vs. Patch Alone for Medically-Ill Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* currently smoking at least 10 cigarettes per day (confirmed by high exhaled carbon-monoxide (CO))~* 18 years or older~* interested in quitting within the next 30 days~* one or more pre-defined medical illnesses (including cardiovascular disease, other vascular disease, chronic pulmonary disease, cancer, hypertension, diabetes, hyperlipidemia, and recurrent pulmonary infections)~Exclusion Criteria:~* contraindications to pharmacotherapy (including unstable angina, myocardial infarction within 2 months, severe arrhythmia, seizure disorder, serious mental illness requiring antipsychotic medications)~* current use of other tobacco products (smokeless tobacco, cigars, pipes, etc.), bupropion, clonidine, nortriptyline, or nicotine replacement medications~* unable to give consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Nicotine patch, nicotine inhaler, bupropion
- 2 (Type: ACTIVE_COMPARATOR): Nicotine patch

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dexamethasone in Postoperative Symptoms After Mastectomy for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists classes I-II female patients with breast cancer scheduled for surgical treatment; mastectomy plus axillary node dissection.~Exclusion Criteria:~* American Society of Anesthesiologists classes III and IV.~* Age more than 80 years; pregnancy; active menstruation; treatment with steroids; severe diabetes mellitus (serum HbA1c \> 8%); use of opioids, sedatives or any kind of analgesics less than one week before mastectomy, or a history of alcohol or drug abuse.~* Patients with any history of motion sickness and or previous postoperative nausea and vomiting after any surgical procedure.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone group (Type: ACTIVE_COMPARATOR): This group of patients received intravenous dexamethasone (8 mg) 60 minutes before skin incision.
- Placebo group (Type: PLACEBO_COMPARATOR): Patients of these group received homologated placebo 60 minutes before skin incision.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Post Sexual Assault Stress

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Seeking medical care after recent sexual assault~Exclusion Criteria:~* Active psychosis Active suicidality Cognitive impairment Non-English speaking Severe injury

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- PPRS video (Type: EXPERIMENTAL): Prevention of post sexual assault stress
- PIRI video (Type: ACTIVE_COMPARATOR): Pleasant imagery and relaxation instruction
- Standard care (Type: NO_INTERVENTION): Treatment as usual

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Participants must meet all of the following criteria:~* Male or Female patients 18 years and older.~* Patient with a diagnosis of chronic myelogenous leukemia in chronic phase~* Within 6 months of initial diagnosis.~* Received any treatment for CML for less than 1 month prior to study entry with the exception of hydroxyurea and/or anagrelide.~Exclusion Criteria:~* Late chronic phase, accelerated phase or blastic phase~* Taking any other investigational agents within 28 days of starting the study~* If sibling donors have been identified and where allogeneic bone marrow transplantation will be the first line treatment.~* Another primary malignancy /cancer unless it is not considered clinically significant or does not require active intervention.~* If patients have heart problems or complications~* Pregnant or breast-feeding females~* Severe and/or uncontrolled disease such as diabetes, chronic renal disease, etc.~* Chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).~* Diagnosis of human immunodeficiency virus (HIV) infection.~* Received any treatment for CML for longer than 1 month prior to study entry with the exception of hydroxyurea and/or anagrelide.~* Patient previously received radiotherapy to greater than 25% of the bone marrow.~* Patient had a major surgery within 4 weeks prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mirena or Conventional Medical Treatment for Menorrhagia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women between the ages of 18-45 (inclusive) not intending to get pregnant during the next year~* Women complaining of heavy menstrual bleeding over several consecutive cycles~* Women without structural or histological abnormality of the uterus, or with fibroids less than 3 cm in diameter which are causing no distortion of the uterine cavity (eligible for pharmaceutical treatment according to the NICE guideline 2007)~* Informed consent (where required by laws or regulations)~Exclusion Criteria:~* The contraindications and warnings of the respective Summary of Product Characteristics (Mirena, combined oral contraceptives, oral/injectable progestogens, non-steroidal anti-inflammatory drug, or anti-fibrinolytic agent) must be followed.~* Women taking hormone replacement therapy~* Women with symptoms such as intermenstrual or post-coital bleeding, unless an endometrial biopsy has been performed and pathology excluded~* Women with fibroids that are palpable abdominally or who have intra-cavity fibroids and/or whose uterine length as measured at ultrasound or hysteroscopy is greater than 12 cm (NICE guideline 2007)~* Women on anticoagulative therapy or other treatment (including e.g. Copper IUD use) known to cause menorrhagia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): None
- Group 2 (Type: None): None
- Group 3 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Sildenafil in Advanced Heart Failure.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Age \>18 years Ejection fraction \<40% Heart failure limited by fatigue and shortness of breath Pulmonary artery hypertension~Exclusion Criteria:~Patients taking the following medications: nitroglycerine pill/patch/paste, isordil, Imdur, antifungal agents and certain antidepressants.~Patients with a history of optic neuropathy or unexplained visual impairment. Patients with anemia.~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Luteal Phase-start Ovarian Stimulation With Corifollitropin Alfa

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy eligible oocyte donors~2. Age 18-34 years~3. AFC \>12 and AMH\>1.5 ng/ml~4. BMI 19-28kg/m2~5. Body weight \>60kg~6. Both ovaries present~7. Willing to participate in the study~8. Willing to use non-hormonal contraception or not needing contraception Recipients will be eligible only if their partners' sperm which will be used for ICSI will be normal. Couples will be excluded in case of moderate to severe oligoasthenospermia.~Exclusion Criteria:~1. Endometriosis~2. AFC\>20~3. PCOS~4. Low ovarian reserve~5. Endocrine abnormalities~6. Hormonal contraception~7. Contraindication of hormonal treatment~8. History of Ovarian Hyperstimulation Syndrome or hyper-response (\> 30 follicles .~11mm)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Early follicular phase protocol (Type: ACTIVE_COMPARATOR): On day 2 or 3 of the menstrual cycle, following baseline blood sampling, a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.
- Luteal phase protocol (Type: EXPERIMENTAL): Following baseline blood sampling on cycle day 2 of 3 of the menstrual cycle, patients will be followed up with blood and ultrasound from cycle day 10 onwards till the detection of serum LH peak. LH peak will be defined as an increase in serum LH above 20IU/LH. Five (5) days after the LH peak a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 - \< 65 years. Histologically confirmed CD20+ diffuse large B-cell lymphoma (DLBCL) based on WHO 2008 Lymphoma Classification~* Follicular lymphomas (FLs) grade 3b is allowed~Patients in at least stage II with age adjusted international prognostic score (IPI score) of 2 or 3:~* Stage III /IV and elevated LDH~* Stage III/IV and WHO performance status 2 - 3~* Stage II and elevated LDH and WHO performance status 2 - 3 And/or patients with~* More than one extranodal site~* Testicular lymphoma, stage IIE and higher~* Paranasal sinus and orbital lymphoma with destruction of bone~* Large cell infiltration of the bone marrow~Exclusion Criteria:~* Severe cardiac disease: cardiac function grade 3-4~* Impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule~* Pregnancy/lactation~* Men and women of reproductive potential not agreeing to use an acceptable method of birth control during treatment and for six months after completion of treatment~* Patients with other severe medical problems and with an expected short survival for non-lymphoma reasons~* Known HIV positivity~* Uncontrolled infectious disease, including meningeal infection~* Active cancer except basal cell carcinoma and cervical carcinoma in situ during the last five years~* Earlier treatment containing anthracyclins~* Psychiatric or mental disorder which make the patient unable to give an informed consent and/or adhere to the protocol~* CNS disease as diagnosed by MRI or cerebrospinal fluid (CSF) cytology. Positive CSF flow cytometry below diagnostic threshold level by cytology is allowed~* Pleural or peritoneal fluid that cannot be drained safely~* Hypersensitivity to the active substance or any of the other ingredients~* Patients participating in other clinical studies, unless followed for survival

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- CNS prophylaxis (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: REACH VET Implementation Program Evaluation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: ECOLOGIC_OR_COMMUNITY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* VA employee at a facility receiving virtual external facilitation~* Involved in REACH VET implementation~Exclusion Criteria:~* Not a VA employee~* Not employed at a facility receiving virtual external facilitation~* Not involved in REACH VET implementation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- VAMC's receiving implementation support for REACH VET (Type: None): This cohort consists of 28 VA Medical Centers (VAMC's) needing additional implementation support to fully implement REACH VET as identified by Veteran Integrated Service Network (VISN) leadership, and that agreed to participate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients who have used interferon beta in last 3 months. Patients with 1-5 EDSS~Exclusion Criteria:~* Patients who have diseases which affect on Th1/Th2 balance such as asthma, active viral infections, and autoimmune diseases, OR~* Patients who have allergy to vitamin A compounds, OR~* Patients who have used vitamin supplements in last 3 months.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- with Multiple Sclerosis/ vitamin A (Type: ACTIVE_COMPARATOR): Patients with MS confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A
- with Multiple Sclerosis/ placebo (Type: PLACEBO_COMPARATOR): Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete